logo
Sign in

INVIRAGEN, INC.

FORT COLLINS, CO · Founded 2006 · UNCERTAIN · Still private

Invalid or insufficient company information provided

Claim this profile

Follows are private to you and power your alerts

Updated · inviragen.com

Sector
UNCERTAIN
Headquarters
FORT COLLINS, CO
Founded
2006
Latest Form D
$4.4M, Oct 2009
Total capital
$26M
Federal grants
$19.4M
21 awards · 2006–2011
21× sector median 1 award
Private capital raised
$6.6M
2 Form D · last Oct 2009
205 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
5 pending

Capital timeline

200620072008200920102011FEDERAL ↑EQUITY ↓Cumulative $26M$1.0M$1.2M$1.8M$1.4M$4.7M$3.2M2nd Form D$4.4M
200620072008200920102011FEDERAL ↑EQUITY ↓Cumulative $26M$1.8M$4.7M$3.2M1st Form D$2.2M2nd Form D$4.4M

Latest events

  • Federal grantHealth and Human S · N01 · Development of Technologies to Facilitate the Use of and Response to Vaccines$3.2M
  • Federal grantHealth and Human S · N01 · Development of Technologies to Facilitate the Use of and Response to Vaccines$4.7M
  • Federal grantHealth and Human S · N01 · Development of Technologies to Facilitate the Use of and Response to Vaccines$1.4M
  • Federal grantHealth and Human S · N01 · Development of Technologies to Facilitate the Use of and Response to Vaccines$1.8M
  • Private capital raisedForm D · SEC · 2nd filing$4.4M
  • Private capital raisedForm D · SEC · 1st filing$2.2M
  • Federal grantHealth and Human S · Phase I · Second Generation Dengue Vaccine$300K
Show 16 earlier federal awards
  • Federal grantHealth and Human S · Phase I · Second Generation Dengue Vaccine$300K
  • Federal grantHealth and Human S · Phase I · Development of a Novel, Chimeric Chikungunya Vaccine$17K
  • Federal grantHealth and Human S · Phase I · Multivalent HPV Capsomere Vaccines$373K
  • Federal grantHealth and Human S · Phase I · Development of a Novel, Chimeric Chikungunya Vaccine$202K
  • Federal grantHealth and Human S · Phase I · Development of a Novel, Chimeric Chikungunya Vaccine$209K
  • Federal grantHealth and Human S · Phase I · MVA-based vaccines against highly pathogenic avian influenza$300K
  • Federal grantHealth and Human S · Phase I · MVA-based vaccines against highly pathogenic avian influenza$289K
  • Federal grantHealth and Human S · U01 · Preclinical development of a chimeric tetravalent dengue vaccine$488K
  • Federal grantHealth and Human S · U01 · Preclinical development of a chimeric tetravalent dengue vaccine$1.2M
  • Federal grantHealth and Human S · U01 · Preclinical development of a chimeric tetravalent dengue vaccine$419K
  • Federal grantHealth and Human S · U01 · Preclinical development of a chimeric tetravalent dengue vaccine$772K
  • Federal grantHealth and Human S · Phase II · Clinical Development of Combination Plague/Smallpox Vaccine$980K
  • Federal grantHealth and Human S · Phase I · Mucosal modified vaccinina Ankara-based plaque vaccines$358K
  • Federal grantHealth and Human S · Phase II · Clinical Development of Combination Plague/Smallpox Vaccine$849K
  • Federal grantHealth and Human S · Phase II · Clinical Development of Combination Plague/Smallpox Vaccine$1.0M
  • Federal grantHealth and Human S · Phase I · Mucosal modified vaccinina Ankara-based plaque vaccines$310K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

43months

from INVIRAGEN, INC.’s first federal award to its first private round.

First federal award · Mar 2006
Health and Human S · $310K
First Form D · Oct 2009
$2.2M · 1st Form D
Awards before first raise
17 awards

An association in public records, not a cause or a prediction.

Founders and team

Researcher links verified by same-company patents and grants
  • DAN STINCHCOMBResearcherExecutive Officer, Director, PromoterLinked by $7.8M in grants as PI
  • FRED TONG SCHWARZERDirectorNamed in SEC Form D filings
  • HENG TONG CHOODirectorNamed in SEC Form D filings
  • JERRY TONG SADOFFDirectorNamed in SEC Form D filings
  • JOHN TONG NEISDirectorNamed in SEC Form D filings
  • JORGE OSORIOExecutive Officer, PromoterNamed in SEC Form D filings
Show all 7 people
  • REX R. O'NEALExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 5
  • PendingCompositions, Methods And Uses For Expression Of Enterobacterium-associated PeptidesUSPTOApplication PCTUS2010058094
  • PendingCompositions, Methods And Uses For Poxvirus Elements In Vaccine ConstructsUSPTOApplication PCTUS2010057682
  • PendingCompositions And Methods For Administration Of Vaccines Against Dengue VirusUSPTOApplication PCTUS2010036726
Show all 5 patent records
  • Compositions, Methods And Uses For Expression Of Enterobacterium-associated PeptidesApplication PCTUS2010058094Pending
  • Compositions, Methods And Uses For Poxvirus Elements In Vaccine ConstructsApplication PCTUS2010057682Pending
  • Compositions And Methods For Administration Of Vaccines Against Dengue VirusApplication PCTUS2010036726Pending
  • Compositions, Methods And Uses For Inducing Viral GrowthApplication PCTUS2009066848Pending
  • Methods And Compositions For Live Attenuated VirusesApplication PCTUS2008059472Pending

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .